Molecules for Biology's Hardest Targets
Pythia Labs is a biotechnology company building frontier AI models for therapeutic discovery. We are beginning with next-generation antibodies for hard-to-drug targets.
Extending the Reach of Antibody Therapeutics
Extending the Reach of Antibody Therapeutics
For decades, antibody discovery has relied on methods such as immunization and library screening. Those approaches have produced important medicines, but they leave much of discovery to chance and remain ineffective across many target classes.
Our technology makes it possible to rapidly create lead candidates for targets that are difficult or impossible to drug through traditional discovery, including multi-pass membrane proteins such as GPCRs and ion channels.
By extending antibody discovery into areas of biology that conventional methods have struggled to access, Pythia's technology creates new opportunities to develop transformative medicines that were previously beyond reach.
Meet our people
Meet our people
Pythia brings together scientists and engineers at the intersection of AI and antibody discovery, with a collective track record of 12+ biologics advanced to the clinic and more than 300 papers and patents across both fields.